Stocktoria
NEUROCRINE BIOSCIENCES INC NBIX
NEUROCRINE BIOSCIENCES INC (NBIX) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $2.9B at a 16.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.47 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-03 | Canaccord Genuity | Buy (main) |
| 2026-08-03 | Truist Securities | Buy (main) |
| 2026-08-03 | Wedbush | Outperform (main) |
| 2026-07-31 | Citigroup | Buy (main) |
| 2026-07-31 | RBC Capital | Outperform (main) |
| 2026-07-31 | Morgan Stanley | Equal-Weight (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.384 |
| Retained earnings / assets | 0.097 |
| EBIT / assets | 0.134 |
| Equity / liabilities | 2.36 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NBIX | NEUROCRINE BIOSCIENCES INC | 5/9 | 6.21 | 35.4 | +21.4% |
| EXEL | EXELIXIS, INC. | 6/9 | 7.69 | 17.6 | +7% |
| QGEN | QIAGEN N.V. | 7/9 | 5.06 | 19.1 | +5.7% |
| HALO | HALOZYME THERAPEUTICS, INC. | 5/9 | 3.02 | 28.1 | +37.6% |
| TECH | BIO-TECHNE Corp | 5/9 | 5.89 | 151.4 | +5.2% |
| NVAX | NOVAVAX INC | 4/9 | -7.28 | 3.3 | +64.7% |
| BCRX | BIOCRYST PHARMACEUTICALS INC | 6/9 | -2.63 | 9.6 | +94.1% |
About NEUROCRINE BIOSCIENCES INC
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
FAQ
Is NBIX financially healthy?
NEUROCRINE BIOSCIENCES INC's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does NBIX pay a dividend?
No, NEUROCRINE BIOSCIENCES INC does not currently pay a dividend.
How profitable is NBIX?
In FY2025, NEUROCRINE BIOSCIENCES INC had a net margin of 16.7% and a return on equity of 14.7%.
Is NBIX overvalued or undervalued?
NEUROCRINE BIOSCIENCES INC trades at about 33.5× trailing earnings — below its 10-year norm (10-year range 13.9×–401.0×, median 71.1×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for NBIX?
The average Wall-Street price target for NEUROCRINE BIOSCIENCES INC is $213.13, about 36.2% above the recent price, from 27 analysts (consensus: strong buy).
Is NBIX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on NEUROCRINE BIOSCIENCES INC: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 35.4×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.